Conferences & Courses
Targeting the Microbiome Targeting the Microbiome
September 22-23, 2015 | Boston, MA
The Targeting the Microbiome Track, taking place at the 13th Annual Discovery on Target Conference September 21-24, 2015 in Boston, MA, tracks the scientific and clinical research and applications being made in microbial targeted therapies for inflammatio

Targeting Ocular Disorders Targeting Ocular Disorders
September 22-23, 2015 | Boston, MA
Targeting Ocular Disorders conference covers promising drug targets, pathways and mechanisms of action for ocular diseases.

Kinase Inhibitor Discovery Kinase Inhibitor Discovery
September 23-24, 2015 | Boston, MA
Discovery on Target's Kinase inhibitors Discovery Conference convenes discovery biologists and chemists to discuss the newest strategies for kinase inhibitor design, to stay abreast of oncology, inflammation and CNS-related kinase inhibitors in the cl




Life Science Media Library
Systems Biology, Synthesis in silico Discovery microRNA Biomarkers DVD Systems Biology, Synthesis in silico Discovery microRNA Biomarkers DVD
March 16, 2015 |
There currently exists no standard systematic way to identify candidate microRNAs for experimental evaluation and verification of their utility as disease biomarkers. In this course we will present a putative framework for the identification of candidate circulating microRNA biomarkers, based on in silico, systems biology and quantitative evidence synthesis techniques. We will discuss the implementation of circulating miRNA studies and examine relevant workflows, specimen collection and handling, quantification and data analysis techniques.
Next Generation Sequencing as a Diagnostics Platform Next Generation Sequencing as a Diagnostics Platform
August 19, 2014 |
Next generation sequencing (NGS) has revolutionized genomics and is now on the verge of being widely adopted for medical sequencing. Until recently, comprehensive genetic testing for genetically heterogeneous diseases was limited by the high cost of traditional (Sanger) sequencing technology. NGS technologies have now completely eliminated this limit such that virtually any gene with a published association to the disease of interest can be tested. Whole exome or whole genome sequencing (WES/WGS) is the ultimate genetic test and many success stories provide a taste of its power. However, while the cost of generating high-quality whole genome sequence data is rapidly dropping, analysis of the enormous number of variants detected is still too complex to implement WGS/WES as a first line genetic test. Targeted NGS-based gene panels are typically an order of magnitude smaller than WES/WGS based testing but follow the same principles. Screening large sets of genes is particularly useful when the clinical diagnosis is uncertain as it eliminates the need for costly and lengthy cascade testing that has dominated genetic testing in the past. Drawbacks are significantly increased numbers of detected variants, which poses novel challenges for post-analytic data analyses. The focus of this short course is on understanding the use of NGS in clinical diagnosis, practical implementation of NGS in clinical laboratories and analysis of large data sets by using bioinformatics tools to parse and interpret data in relation to the clinical phenotype. The concluding presentation is dedicated to quality and standardization of NGS assays.
Overcoming Challenges of Working with FFPE Samples Overcoming Challenges of Working with FFPE Samples
August 18, 2014 |
The course provides important insights for overcoming challenges of working with FFPE samples for cancer research such as detecting RNA and profiling miRNA expression. Next generation sequencing (NGS) utilizes FFPE samples for clinical retrospective studies. Successful interpretation of the samples depends on the quality of the starting material.




Publications, Reports, & Whitepapers
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Mgmt
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). This report also details the commercial aspects, market dynamics, and trends of liquid biopsy.













CII Offerings
  • PepTalk 2016
  • MMTC16 Icon
  • SCOPE Icon
  • BioITWorld_scroll_81015
  • Drug Discovery Chemistry_scroll_81015
  • PEGS_scroll_81015
  • Biomarkers & Diagnostics World Congress_scroll_81015
  • World Preclinical Congress_scroll_81015
  • Bioprocess Summit_81015
  • Next Generation DX Summit_81015
  • DOT Icon